AR095885A1 - Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 - Google Patents
Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2Info
- Publication number
- AR095885A1 AR095885A1 ARP140101626A ARP140101626A AR095885A1 AR 095885 A1 AR095885 A1 AR 095885A1 AR P140101626 A ARP140101626 A AR P140101626A AR P140101626 A ARP140101626 A AR P140101626A AR 095885 A1 AR095885 A1 AR 095885A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- carbonitrile
- pyrrolo
- pyridine
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 title abstract 2
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000005262 alkoxyamine group Chemical group 0.000 abstract 2
- 150000003973 alkyl amines Chemical class 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- VYEFDAQRXKQMPZ-UHFFFAOYSA-N 4-(2,4-dimethylphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC(C)=CC=C1C1=CC=NC2=C1C(C#N)=CN2 VYEFDAQRXKQMPZ-UHFFFAOYSA-N 0.000 abstract 1
- NSJGIUMXLVXGPU-UHFFFAOYSA-N 4-(3-hydroxyphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound OC1=CC=CC(C=2C=3C(C#N)=CNC=3N=CC=2)=C1 NSJGIUMXLVXGPU-UHFFFAOYSA-N 0.000 abstract 1
- WRQMDDJZRIRGLV-UHFFFAOYSA-N 4-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound N#Cc1c[nH]c2nccc(-c3ccccc3)c12 WRQMDDJZRIRGLV-UHFFFAOYSA-N 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201300231 | 2013-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095885A1 true AR095885A1 (es) | 2015-11-18 |
Family
ID=59093654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101626A AR095885A1 (es) | 2013-04-18 | 2014-04-16 | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9499542B2 (enExample) |
| EP (1) | EP2986608B1 (enExample) |
| JP (1) | JP6461097B2 (enExample) |
| CN (1) | CN105263930B (enExample) |
| AR (1) | AR095885A1 (enExample) |
| ES (1) | ES2642204T3 (enExample) |
| TW (1) | TW201533043A (enExample) |
| WO (1) | WO2014170248A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| JP2018537502A (ja) | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法 |
| PT3472153T (pt) * | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) * | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| WO2018155947A1 (ko) | 2017-02-24 | 2018-08-30 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| AU2018239798B2 (en) | 2017-03-23 | 2020-08-27 | Daegu Gyeongbuk Institute Of Science And Technology | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases |
| JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
| SG11202005264PA (en) * | 2017-12-05 | 2020-07-29 | Oscotec Inc | Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| RU2020118913A (ru) | 2017-12-14 | 2022-01-14 | Х. Лундбекк А/С (H. Lundbeck A/S) | Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
| WO2020023393A1 (en) * | 2018-07-23 | 2020-01-30 | Bioblocks, Inc. | Kinase antagonists and methods for making and using them |
| KR101990739B1 (ko) * | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR101992059B1 (ko) * | 2018-08-23 | 2019-06-21 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CA3168211A1 (en) | 2019-01-18 | 2020-07-23 | Voronoi Co., Ltd. | Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease |
| KR102133595B1 (ko) * | 2019-05-31 | 2020-07-13 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR20230091150A (ko) * | 2020-10-29 | 2023-06-22 | 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 | 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도 |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| CN112852954A (zh) * | 2021-03-16 | 2021-05-28 | 江苏贝格尔生物医药有限公司 | 一种检测lrrk2基因1628多态性的引物和探针及试剂盒 |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| US20250361230A1 (en) * | 2022-06-06 | 2025-11-27 | The USA, as Represented by the Secretary, Dept. of Heath and Human Services | LATS Inhibitors and Uses Thereof |
| CN119707961B (zh) * | 2024-12-02 | 2025-10-24 | 重庆飞因科生物科技有限公司 | 吡啶并吡咯类氨基酸衍生物及其在制备富亮氨酸重复激酶2抑制剂中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004101565A2 (en) | 2003-05-16 | 2004-11-25 | Eisai Co., Ltd. | Jnk inhibitors |
| EP1968568A4 (en) | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
| EP1979353A2 (en) * | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| WO2007090141A2 (en) * | 2006-02-01 | 2007-08-09 | Smithkline Beecham Corporation | Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors |
| GB0617161D0 (en) | 2006-08-31 | 2006-10-11 | Vernalis R&D Ltd | Enzyme inhibitors |
| WO2008110508A1 (en) * | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity |
| NZ579635A (en) | 2007-03-20 | 2011-07-29 | Curis Inc | Fused amino pyridine as hsp90 inhibitors |
| KR101700229B1 (ko) * | 2009-03-19 | 2017-01-26 | 메디칼 리서치 카운실 테크놀로지 | 화합물들 |
| GB201008134D0 (en) * | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| KR101984480B1 (ko) | 2011-04-05 | 2019-05-31 | 슬로안-케테링인스티튜트퍼캔서리서치 | Ｈｓｐ９０ 억제제 |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
-
2014
- 2014-04-08 TW TW103112818A patent/TW201533043A/zh unknown
- 2014-04-14 WO PCT/EP2014/057482 patent/WO2014170248A1/en not_active Ceased
- 2014-04-14 EP EP14720062.0A patent/EP2986608B1/en active Active
- 2014-04-14 JP JP2016508109A patent/JP6461097B2/ja not_active Expired - Fee Related
- 2014-04-14 US US14/777,805 patent/US9499542B2/en not_active Expired - Fee Related
- 2014-04-14 ES ES14720062.0T patent/ES2642204T3/es active Active
- 2014-04-14 CN CN201480021665.9A patent/CN105263930B/zh active Active
- 2014-04-16 AR ARP140101626A patent/AR095885A1/es unknown
- 2014-04-17 US US14/255,317 patent/US20140315901A1/en not_active Abandoned
-
2016
- 2016-10-07 US US15/288,255 patent/US9675594B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2986608A1 (en) | 2016-02-24 |
| HK1222387A1 (en) | 2017-06-30 |
| JP6461097B2 (ja) | 2019-01-30 |
| JP2016516791A (ja) | 2016-06-09 |
| CN105263930B (zh) | 2017-06-09 |
| US9675594B2 (en) | 2017-06-13 |
| US20160102089A1 (en) | 2016-04-14 |
| TW201533043A (zh) | 2015-09-01 |
| US20140315901A1 (en) | 2014-10-23 |
| ES2642204T3 (es) | 2017-11-15 |
| EP2986608B1 (en) | 2017-08-23 |
| WO2014170248A1 (en) | 2014-10-23 |
| US9499542B2 (en) | 2016-11-22 |
| US20170020850A1 (en) | 2017-01-26 |
| CN105263930A (zh) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| TR201904658T4 (tr) | Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları. | |
| AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR101456A1 (es) | Inhibidores de cinasa c de proteína y métodos para usarse | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| MA40170A (fr) | Dérivés hétérocycliques de morphinan et leur utilisation | |
| CU20170007A7 (es) | Compuestos de imidazopiridazina | |
| UY36124A (es) | Derivados de carboxamida | |
| AR097739A1 (es) | Imidazo[1,2-a]piridina-7-aminas | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| UY36123A (es) | Derivados de carboxamida | |
| EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |